Treatment
Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC)
Journal of Thoracic Disease 2026 May 31 [Link] Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, Arjang Ruhparwar, Hayan Merhej, Patrick Zardo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel…
Read MoreRejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma
Research 2026 June 11 [Link] Yan-Ruide Li, Yichen Zhu, Zhe Li, Xinyuan Shen, Shuo Li, Yuning Chen, Zibai Lyu, Jie Huang, Nathan Y Ma, Catherine Zhang, Annabel S Zhao, Yanxin Tian, Xianghong Jasmine Zhou, Lili Yang Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy arising from the pleural lining, characterized by…
Read MoreThe Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves
Current Oncology Reports 2026 June 8 [Link] Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta Abstract Purpose of review: Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum-pemetrexed chemotherapy has persisted as the…
Read MoreProtein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells
Cellular Oncology 2026 June 8 [Link] Eleonora Nigliato, Yan Ma, Rita Derua, Maria Butyrin, Sandra P Nunes, Léa Guilmot, Antonio De Gianni, Rüveyda Dok, Andrew P Feld, Michael Ohlmeyer, Brian E Wadzinski, Sandra Nuyts, Ilaria Elia, Anna Sablina, Veerle Janssens Abstract Purpose: Malignant pleural mesothelioma (MPM) is a rare cancer of the pleura, frequently related…
Read MoreA single-center experience in parenchyma-sparing surgical treatment of malignant pleural mesothelioma
Updates in Surgery 2026 June 1 [Link] Giuseppe Mangiameli, Debora Brascia, Emanuela Re Cecconi, Veronica Maria Giudici, Edoardo Bottoni, Alessandro Crepaldi, Umberto Cariboni, Alberto Testori, Paolo Zucali, Matteo Perrino, Nadia Cordua, Armando Santoro, Marco Alloisio, Giuseppe Marulli Abstract The role of surgery in malignant pleural mesothelioma (MPM) remains controversial, particularly after the negative results of…
Read MoreConditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma
Scientific Reports 2026 June 1 [Link] Xiaofeng Liao, Chen Li, Ming Huang, Zheng Yao, Shikun Luo, Xiaoyu Lei Abstract Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer with limited treatment options and extremely poor survival outcomes. Due to the disease’s low incidence, large-scale cohort studies to clarify survival outcomes and the impact of treatments…
Read MoreFeasibility and Outcomes of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 May 28 [Link] Yota Suzuki, Inderpal S Sarkaria, Edra Ha, Ian G Christie, Olugbenga T Okusanya, Omar Awais, Evan T Alicuben, Ryan M Levy, James D Luketich, Neil A Christie Abstract Background: The management of pleural mesothelioma requires a multidisciplinary approach, and hyperthermic intrathoracic chemoperfusion (HITHOC) after surgical cytoreduction…
Read MoreA High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma
Cancers 2026 May 7 [Link] Zivile Useckaite, Ashleigh J Hocking, Lauren A Mortimer, John Salamon, Simon Lee, Yazad Irani, Lucy Franzon, Arya L Arul, Sarita Prabhakaran, Sonja Klebe Abstract Background: Pleural mesothelioma (PM) is characterised by often rapid therapeutic failure and chemotherapy resistance. While terminal resistance is well studied, the initial transition into a drug-tolerant…
Read MoreThe role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy
Lung Cancer 2026 July [Link] Farhad Kosari, Paul Baas, Maria Disselhorst, Kim Lauer, Tobias Peikert, Stephen Murphy, Janet Schaefer Klein, Aaron S Mansfield Abstract Assessing the contributions of microRNAs to gene expression regulation and treatment outcomes in malignancies is challenging. Traditional analyses focus on individual microRNAs, overlooking competitive binding among RNA species sharing common microRNAs.…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read More
Skip to content